-
公开(公告)号：EP4112054A1
公开(公告)日：2023-01-04
申请号：EP21760664.9
申请日：2021-02-26
申请人： Shanghai Runshi Medical Technology Co., Ltd , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： ZHANG, Ao , GENG, Meiyu , AI, Jing , WANG, Caixia , PENG, Xia , ZHANG, Yang , DING, Jian
IPC分类号： A61K31/4427 , A61K31/44 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/506 , A61K31/4433 , C07D401/12 , C07D213/75 , C07D413/12 , C07D417/12 , C07D403/12 , C07D405/12 , A61P35/00
摘要： Use of a compound of general formula (A) which is a CFS-1R kinase inhibitor or a pharmaceutically acceptable salt thereof in the preparation of medicaments for treating diseases related to CSF-1R kinase signal transduction pathway or medicaments for regulating immunization. In vivo and in vitro studies show that the compound can significantly inhibit CSF-1R kinase activity; significantly inhibits the proliferation of a CSF-1/CSF-1R-driven mouse myeloid leukemia cell line, inhibits the survival of macrophages induced by CSF-1 and reverses M2 polarization phenotype of macrophages, and has an effect superior to that of the marketed medicament Pexidartinib. In a TAM enriched tumor model (MC38 model), the compound significantly antagonizes the tumor immunosuppressive microenvironment and exhibits significant anti-tumor efficacy. The compound has inhibitory effects on tumors that are not sensitive to immune checkpoint drugs, and can enhance the efficacy of immune checkpoint drugs, and has good clinical application prospects.
-
公开(公告)号：EP4053124A1
公开(公告)日：2022-09-07
申请号：EP20881171.1
申请日：2020-10-23
发明人： DUAN, Wenhu , GENG, Meiyu , ZHAN, Zhengsheng , XIE, Zuoquan , ZHAO, Kaiyan , GUO, Yuting , WANG, Xiyuan , ZHANG, Yan , ZHOU, Xiaoqian , DING, Jian
IPC分类号： C07D409/04 , C07D409/14 , C07D407/04 , C07D333/00 , C07D231/56 , C07D493/00 , C07D487/00 , A61K31/381 , A61K31/403 , A61K31/343 , A61K31/357 , A61P35/00 , A61P37/00
摘要： The present invention relates to a five-membered heterocyclic oxocarboxylic acid compound and the medical use thereof. Specifically, the present invention relates to a compound as represented by formula (I) and a pharmaceutically acceptable salt, prodrug, hydrate, solvate or crystal form thereof, and also relates to a method for preparing the compound, a pharmaceutical composition containing the compound, and the medical use thereof as a secretion regulator of type I interferon, especially as a STING agonist, and in the preparation of a drug for preventing and/or treating diseases related to type I interferon.
-
33.发明公开
公开(公告)号：EP4011395A1
公开(公告)日：2022-06-15
申请号：EP20850878.8
申请日：2020-08-05
申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： GENG, Meiyu , SUN, Guangqiang , WANG, Xinyi , ZHANG, Jing , FENG, Teng
摘要： The present invention relates to identification of a carbohydrate drug-sensitive patient in patients having Alzheimer's disease. The present invention provides a method for identifying a carbohydrate drug-sensitive patient in patients having Alzheimer's disease.
-
34.发明公开
公开(公告)号：EP4011394A1
公开(公告)日：2022-06-15
申请号：EP20850618.8
申请日：2020-08-05
申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： GENG, Meiyu , SUN, Guangqiang , WANG, Xinyi , ZHANG, Jing , FENG, Teng
IPC分类号： A61K45/00 , A61K31/702 , G01N33/483 , A61P3/10
摘要： Provided is the use of a reagent for inhibiting the uptake of amino acids by naive T cells in the preparation of a drug for treating Alzheimer's disease in a subject.
-
公开(公告)号：EP4011392A1
公开(公告)日：2022-06-15
申请号：EP20849639.8
申请日：2020-08-05
申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： GENG, Meiyu , SUN, Guangqiang , WANG, Xinyi , ZHANG, Jing , FENG, Teng
摘要： The present invention relates to the treatment of Alzheimer's disease. Provided is the use of an reagent for regulating the relative abundance of intestinal microorganisms in the preparation of a medicament for treating Alzheimer's disease in a subjet.
-
公开(公告)号：EP4011379A1
公开(公告)日：2022-06-15
申请号：EP20850067.8
申请日：2020-08-05
申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： GENG, Meiyu , SUN, Guangqiang , WANG, Xinyi , ZHANG, Jing , FENG, Teng
IPC分类号： A61K31/702 , G01N33/483 , A61P25/28 , A61K45/00
摘要： Provided is a use of an agent for regulating an amino acid level in preparing a drug for treating Alzheimer's disease in a subject.
-
37.发明公开
公开(公告)号：EP3907221A1
公开(公告)日：2021-11-10
申请号：EP19907455.0
申请日：2019-12-31
发明人： ZHANG, Ao , GENG, Meiyu , DING, Chunyong , XIE, Zuoquan , DING, Jian , ZHANG, Yan , SHEN, Ancheng , WANG, Xiyuan
IPC分类号： C07D333/60 , C07D333/58 , C07D333/56 , C07D409/12 , A61K31/381 , A61P35/00
摘要： The present invention relates to fluorine-containing substituted benzothiophene compound, and a pharmaceutical composition and an application thereof. Specifically, the compound of the present invention has the structure as shown in formula I, wherein the definitions of each group and substituent are as described in the description. The present invention further discloses a preparation method of the compound and an anti-tumor application thereof.
-
公开(公告)号：EP3815693A1
公开(公告)日：2021-05-05
申请号：EP19825915.2
申请日：2019-06-28
申请人： Shanghai Green Valley Pharmaceutical Co., Ltd. , Shanghai Institute of Materia Medica, Chinese Academy of Sciences
发明人： GENG, Meiyu , XIN, Xianliang , ZHANG, Zhenqing , DING, Jian
IPC分类号： A61K31/702 , A61P29/00
摘要： The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of inflammation.
-
公开(公告)号：EP3012259B1
公开(公告)日：2020-06-03
申请号：EP14813825.8
申请日：2014-06-18
申请人： Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai Haihe Pharmaceutical Co., Ltd.
发明人： SHEN, Jingkang , GENG, Meiyu , DING, Jian , XIONG, Bing , AI, Jing , MA, Yuchi , WANG, Xin , PENG, Xia , CHEN, Yuelei , CHEN, Danqi , MENG, Tao , MA, Lanping , JI, Yinchun
IPC分类号： C07D471/04 , C07D487/04 , C07D495/04 , C07D519/00 , A61K31/437 , A61K31/635 , A61K31/5025 , A61K31/519 , A61K31/444 , A61K31/496 , A61K31/5377 , A61K31/4545 , A61P35/00 , A61P35/04
-
公开(公告)号：EP3563853A1
公开(公告)日：2019-11-06
申请号：EP17888733.7
申请日：2017-12-27
发明人： GENG, Meiyu , DING, Jian , ZHANG, Zhenqing , XIAO, Zhongping , DU, Xiaoguang , XIN, Xianliang
IPC分类号： A61K31/7016 , A61K31/702 , A61K31/734 , A61P25/28 , A61P9/00 , C08B37/04 , C07H3/04 , C07H3/06 , C07H1/00
摘要： The present invention relates to a mannuronic diacid oligosaccharide composition, comprising a mannuronic diacid of Formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 9, m is 0, 1 or 2, and m' is 0 or 1, and wherein the total weight of mannuronic diacids wherein n = 1-5 is 80-95% of the total weight of the composition, and the ratio of the total weight of mannuronic diacids wherein n = 1-3 to the total weight of mannuronic diacids wherein n = 4-7 is between 1.0 and 3.5.
-
-
-
-
-
-
-
-
-
搜索结果
43 条记录 (耗时 0.021 秒)
